Procoagulatio, hypercoagulatio és fibrinolysis "shut down" kimutatása ClotPro® viszkoelasztikus tesztek segítségével COVID-19-betegekben.

CONCLUSION: These findings encourage further investigations to elucidate the underlying pathophysiology of thromboembolic events in COVID-19 patients and may support the introduction of full dose anticoagulation with or without antiplatelet therapy. Interventional clinical trials may be helpful in defining the appropriate drug(s), for this purpose, the algorithms of administration, and the optimal duration of therapy. At present, the authorization of a clinical trial that attempts to answer these questions is in progress. Orv Hetil. 2020; 161(22): 899-907.
PMID: 32453702 [PubMed - as supplied by publisher]

Source: Orvosi Hetilap - April 30, 2020 Category: General Medicine Authors: Zátroch I, Smudla A, Babik B, Tánczos K, Kóbori L, Szabó Z, Fazakas J Tags: Orv Hetil Source Type: research